Director Alain J. Cohen withdraws; board commits to gender-diverse appointments

C4 Therapeutics, Inc.

Alain J. Cohen withdrew as director nominee for re-election at 2022 annual meeting; no disagreements with company.
Cohen will cease serving as director and compensation committee member on June 22, 2022.
Board will not nominate a replacement director for the 2022 annual meeting.
Board committed to appoint two gender-diverse directors by the next annual meeting.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Alain J. Cohen

director

CCCC · C4 Therapeutics, Inc.

Effective: 2022-06-22
Filed: June 17, 2022, 7:59 PM ET

On June 15, 2022, Alain J. Cohen notified the Board of Directors (the “ Board ”) of C4 Therapeutics, Inc. (the “ Company ”) of his withdrawal as a director nominee for re-election at the 2022 Annual Meeting of Stockholders.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Alain J. Cohen departed as director at C4 Therapeutics, Inc..

Action: withdrew
Role: director

Exact text from the filing

On June 15, 2022, Alain J. Cohen notified the Board of Directors (the “ Board ”) of C4 Therapeutics, Inc. (the “ Company ”) of his withdrawal as a director nominee for re-election at the 2022 Annual Meeting of Stockholders.

View on SEC.gov

C4 Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-22-023555

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.